Is Equillium's AhR/miR-124 Axis the Key to Unlocking Inflammatory Disease Treatment

Related Articles

Is RAAA the Key to Unlocking Institutional-Grade Income

5 months ago

What Does Recent Insider Selling Signal for Equillium (EQ) Investors

7 months ago

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

7 months ago

What Makes Silk Road Medical's TCAR a Game Changer in Carotid Artery Disease Treatment

6 months ago

Category

You may also like

Stock News•1 months ago

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium plans a Q4 Phase I start for EQ504, an oral AhR modulator for ulcerative colitis, per CSO Stephen Connelly. The company also outlined an oral bispecific peptide for celiac disease.

EQ

Share

Stock News•2 months ago

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

AC Immune reported positive interim Phase 1 data for NLRP3 inhibitor ACI-19764 in a first-in-human study, targeting inflammation. The results support further development, though no specific efficacy o...

ACI

Share

Stock News•3 months ago

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS

Kyverna Therapeutics is positioned to pioneer autoimmune CAR T with miv-cel, targeting FDA approval by late 2026 after regulatory alignment for a rolling BLA submission in SPS. The company holds $236M...

CAR

Share